The abstract is read at the publisher; the summary is JClub's.
Increasing purine biosynthesis with 5-aminoimidazole-4-carboxamide riboside (AICAr) mitigated APOL1 G2/G2 risk variant–linked kidney injury, reducing albuminuria in IFN-γ treated transgenic mice.
- Why it matters: APOL1 nephropathy has genetic and environmental triggers, but how APOL1 risk variants reroute metabolic homeostasis to worsen disease is unclear, limiting targeted interventions.
- What they did: The study used IFN-γ adenovirus–induced APOL1 BAC transgenic mice and tetracycline-inducible cell lines, combining nontargeted glomerular metabolomics with pathway and transcriptional analyses, then testing AICAr in cells and mice.
- The result: Purine metabolism was the strongest differentiator between risk (G1/G1, G2/G2) and nonrisk (G0/G0) genotypes; AICAr rescued purine biosynthesis, reduced cytotoxicity, boosted ATP, lowered kidney phosphorylated AMP-activated protein kinase, and reduced albuminuria.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.